Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): Study of toxicity and efficacy;Intérêt des injections de lymphocytes allogéniques au cours de l'allogreffe de cellules souches hématopoïétiques

Bulletin du Cancer

Volumn 90, Issue 8-9, 2003, Pages 758-762

  Michallet, Anne Sophie ^a   Nicolini, F ^a   Michallet, Mauricette ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bone marrow transplantation; Lymphocyte

Indexed keywords

ACUTE GRAFT REJECTION; ALLOGRAFT; ALLOIMMUNITY; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CANCER RECURRENCE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; DONOR; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; INFUSION; LEUKEMIA; LYMPHOCYTE; LYMPHOCYTOPENIA; RETROSPECTIVE STUDY; T LYMPHOCYTE; TOXICITY; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0141887616     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Crossland KD, Lee VK, Chen W, Riddell SR, Greenberg PD, Cheever MA. T cells from tumor immune mice non specifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 1991; 146: 4414-20.
2. Gale RP, Horowitz MM. Graft-versus-leukemia in bone marrow transplantation: the Advisory Commitee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1990; 1: 94-7.
3. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, et al. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standart risk leukemias. Lancet 1987; 2: 175-8.
4. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leucocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-5.
5. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-54.
6. Blaise D, Olive D, Michallet M, Marit C, Leblond V, Maraninchi D. Impairment of leukemia free survival by addition of interleukine-2-receptor antibody to standart graft-versus-host prophylaxis. Lancet 1995; 345: 1144-6.
7. Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120: 646.
8. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-33.
9. Blaise D, Gravis G, Maraninchi D. Long-term follow-up of T-cell depletion for bone marrow transplantation. Lancet 1993; 341: 51-2.
10. Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997; 9: 139-45.
11. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-53.
12. Tricor G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-8.
13. Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J, et al. Successful treatment of metastatic renal cell carcinoma with a non myeloablative allogenic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 1: 2044-49.
14. Giralr S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-43.
15. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relpase after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.
16. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-8.
17. Bacigalupo A, Soracco M, Vassallo F, Abate M, Van Lin MT, Gualandi F, et al. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 927-32.
18. Guglielmi C, Atcese W, Dazzi F, Brand R, Bunjes D, Verdondk LF, et al. Donor lymphocyte infusion for relpased chronic myelogenous leukemia: pronostic relevance of the initial cell dose. Blood 2002; 100: 397-405.
19. Raiola AM, Van Lint MT, Valbonesi M, Lamparelli T, Gualandi F, Occhini D, et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003; 31: 687-93.
20. Van Rhee F, Savage D, Blackwell J, Orchatd K, Dazzi F, Lin F, et al. Adoptive immunotherapy for relpase of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998; 21: 1055-61.
21. Belluci R, Edwin P, Weller E, Chillemi A, Hichberg E, J.Wu C, et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood 2002; 99: 4610-16.
22. Wu CJ, Chillemi A, Alyea EP, Orsini E, Neuberg D, Soiffer RJ, et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood 2000; 95: 352-9.
23. Slavin S, Ackerstein A, Kedar E. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control minimal residual disease in malignant hematologic disorders. Blood 1991; 46: 1212-5.
24. Terenzi A, Aristei C, Aversa F, Petruccio K, Chionne F, Raymondi C. Efficacity of fludarabine as an immunosuppressor for bone marrow transplantation conditioning: preliminary results. Transplant Proc 1996; 28: 3101.
25. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignat and nonmalignant hematologic diseases. Blood 1998; 78: 756-63.
26. Khouri IF, Keating M, Korbling M. Transplant-like: induction of graft-versus-maligancy using fludarabine-based non-ablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid maligancy. J Clin Oncol 1998; 16: 2817-24.
27. Michaller M, Bilger K, Garban F, Artal M, Huyn A, Blaise D, et al. Allogeneic hematopoietic stem-cell transplantation after non-myeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 2001; 19: 3340-9.
28. Storb R. Non myeloablative hematopoietic stem cell transplantation: replacing cytotoxic therapy by the graft-versus-tumor effect. Ann Y Acad Sci 2001; 938: 328-37.
29. Mohry M, Bay JO, Faucher C, Choufi B, Bilger K, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with anti-thymocyte globulin-base-reduced-intensity preparative regimen. Blood 2003; 102: 470-6.
30. Slavin S, Ackerstein A, Morecki S, Gelfand Y, Cividalli G. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes. Bone Marrow Tranplant 2001; 28: 795-8.
31. Zheng C, Osrad M, Andersson M, Celsing F, Holm G, Sundblad A. Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma. Br J Haematol 2002; 118: 778-85.